|Bid||1.7000 x 900|
|Ask||2.0500 x 4000|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 9, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
Vaping is a growing trend among youngsters, but Trump's recent threat to ban flavored e-cigarettes raises questions. Will traditional cigarette get back its lost glory?
President and CEO of 22nd Century Group Inc (30-Year Financial, Insider Trades) Clifford B Fleet (insider trades) bought 100,000 shares of XXII on 08/27/2019 at an average price of $1.9 a share. Continue reading...
If you're interested in 22nd Century Group, Inc. (NYSEMKT:XXII), then you might want to consider its beta (a measure...
LOS ANGELES, CA / ACCESSWIRE / August 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted (again) as of August 1, 2019. LD Micro has always held the belief that our ...
The big shareholder groups in 22nd Century Group, Inc. (NYSEMKT:XXII) have power over the company. Large companies...
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis research, announced today the appointment of Michael J. Zercher as the Company’s Chief Operating Officer. “Since joining 22nd Century in 2016, Mike has become a highly valued member of our team providing critical leadership in several areas of our business. James W. Cornell, Director & Chairman of the Board of 22nd Century Group added, “Mike will drive our efforts to successfully bring 22nd Century’s proprietary VLNC cigarettes to market in the U.S. and internationally, as well as lead our Company’s strategic expansion in the hemp/cannabis space.
The Williamsville, New York-based company said it had a loss of 2 cents per share. The plant biotechnology company posted revenue of $6.3 million in the period. The company's shares closed at $2.21. A ...
22nd Century’s proposed VLN™ cigarettes continue to fall squarely within the nicotine range that public health officials anticipate will be mandated by the FDA. 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that the Company filed its 2019 First Quarter Report on Form 10-Q with the U.S. Securities and Exchange Commission. The Company will provide a business update for investors on a conference call to be held Wednesday, May 8, 2019, at 4:00 PM (Eastern Time).